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AbstrACt
Introduction Approximately 20%–30% of patients with 
ulcerative colitis (UC) require surgery, the majority of these 
being elective due to chronic symptoms refractory to 
medical treatment. The decision for surgery is dificult and 
dependent on patient preferences. Current resources for 
patients considering surgery have been found not to meet 
minimum international standards. The overall aim of the 
‘DISCUSS’ study is to develop and evaluate a new patient 
decision aid (PtDA) for patients considering surgery for UC 
created in line with international minimum standards.
Methods and analysis This is a prospective mixed- 
methods study of adults (18+ years) who are considering 
surgical intervention for UC across two regional centres 
in Yorkshire, UK. This study is in three stages. In stage 1 
we will develop the PtDA and its content via systematic 
reviews and a patient questionnaire. In stage 2 we will 
assess the face validity of the PtDA using mixed- methods 
on key stakeholders using both semistructured interviews 
and questionnaires, following which the PtDA will be 
reined. In stage 3 we will assess the acceptability of using 
the PtDA in clinical practice. This will use a mixed- methods 
approach on clinicians and patients who are considering 
undergoing elective surgery. Questionnaires including 
the Preparation for Decision- Making Scale, a measure 
of anxiety and decisional conlict will be analysed at two 
timepoints using paired sample t- tests and CIs. Interviews 
with patients and clinicians will be analysed using 
thematic analysis.
Ethics and dissemination Research ethics approval from 
North East–Tyne & Wear South Research Ethics Committee 
(Ref: 19/NE/0073) and Health Research Authority approval 
(Ref: 257044) have been granted. Results will be published 
in open access peer- reviewed journals, presented in 
conferences and distributed through the Crohn’s and 
Colitis UK charity. External endorsement will be sought 
from the International Patient Decision Aid Standards 
Collaboration inventory of PtDAs.
PrOsPErO registration number CRD42018115513, 
CRD42019126186, CRD42019125193.
IntrOduCtIOn
the rationale for the study
Ulcerative colitis (UC) is a chronic, relapsing 
and remitting inflammatory condition of the 
colon and rectum. It causes debilitating symp-
toms such as bleeding per rectum, increased 
stool frequency, abdominal pain and 
tenesmus.1 Symptoms can be managed using 
medical therapies such as aminosalicylates, 
corticosteroids, biologic agents (anti- tumour 
necrosis factor-α or anti- integrin) and tofaci-
tinib.2–5 However, approximately 20%–30% of 
patients with UC will require surgery during 
their disease course.6 A minority of patients 
will require emergency surgery—but the 
majority of patients have elective surgery due 
to chronic symptoms, refractory to medical 
treatment.7 Individuals therefore make a 
choice, or series of choices, to continue with 
strengths and limitations of this study
 Ź This study will develop and evaluate a new patient 
decision aid (PtDA) for patients considering surgery 
for ulcerative colitis which will meet minimum inter-
national standards. This is a preliminary pilot study.
 Ź This study will provide evidence for its acceptabil-
ity and value to patients in routine clinical practice 
when considering surgery for ulcerative colitis.
 Ź This study will also provide evidence of the accept-
ability of the PtDA from the clinicians’ perspective 
and the feasibility of use in routine clinical practice.
 Ź This study will not provide evidence on the value of 
the PtDA nationally. However, it will provide evidence 
across two large regional centres in Yorkshire which 
may be used to form the study design of a national 
evaluation.
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medical treatment or undergo surgery. Surgery may be 
undertaken with the intention of proceeding to further 
reconstructive surgery to restore continuity of the gastro-
intestinal tract, or remaining with a permanent ileostomy.
The decision to opt for elective surgery is described as 
preference sensitive as the preferred treatment option is 
dependent on patient preferences due to clinical equi-
poise between the options.8 The same can be said for the 
decision between reconstructive surgery versus perma-
nent ileostomy. The impact on lifestyle of these two 
choices cannot be understated—reconstructive surgery 
will avoid a stoma, with an acceptance of potential compli-
cations such as increased stool frequency, pouchitis or 
faecal incontinence.9 A stoma may offer more control 
over excretory functions, but is associated with compli-
cations such as parastomal hernia, as well as psycholog-
ical sequelae.10 11 When selecting a treatment option, it 
is clear that the patient must select the option based on 
their preferences.
Shared decision- making is a process whereby clinicians 
share information about treatment options, empow-
ering the patient to make a decision based on their pref-
erences.12 Providing clear and balanced preoperative 
information is a major prerequisite to informed decision- 
making.12 13 The National Institute for Health and Care 
Excellence guidelines for UC emphasise the importance 
of providing such information, but note that no high- 
quality studies assessing the desired content of informa-
tion were available on which to base recommendations.14 
As such clinicians lack guidance on patient informational 
preferences on which to base discussions during consul-
tations. Clinician preferences can be misaligned with 
patient preferences, especially when considering surgical 
options for UC,15 forming a barrier to decision- making 
in this population. Preoperative discussions may also be 
limited by ‘implicit persuasion’—a process whereby clini-
cians subconsciously place greater emphasis on treat-
ment options they believe are suited to the patient.16 
Lack of time in clinic, as well as the lack of guidance on 
the content of preoperative consultations, may provide 
limitations in the shared decision- making process for 
patients with UC.17
Patient decision aids
Patient decision aids (PtDA) are specially created 
tools which aim to improve patient knowledge and aid 
decision- making.18 19 They are evidence based, using the 
most up- to- date clinical evidence, studies assessing patient 
informational preferences and evidence on how patients 
make decisions.20 PtDAs can be used within the clinical 
encounter, by the clinician, to provide structure to consul-
tations, but also by the patients outside the encounter to 
aid their deliberation—a key step to informed consent.13
A systematic review of PtDAs in surgery has illustrated 
their role in improving knowledge, reducing decisional 
conflict and increasing patient input into decision- 
making.21 A satisfactory PtDA for patients considering 
surgery for UC is not currently available. The single 
aid registered on the Decision Aids Library Inventory22 
does not meet minimum standards laid out by the Inter-
national Patient Decision Aid Standards (IPDAS),23 
which have established clear guidance for the systematic 
development of a PtDA.24 This can be summarised into 
three stages, as previously described by members of our 
research group,25 and forms the methodology behind this 
protocol. It is therefore proposed that a new PtDA for 
patients considering surgery for UC, created in line with 
minimum standards, will work towards filling an informa-
tional need for both patients and clinicians.14 26
Aims and objectives
The aim of this research is to develop, assess and validate 
a PtDA for patients considering elective surgery for UC; 
that is, whether to continue with their current medical 
treatment, or whether to undergo surgery. This will also 
include information on the different surgical options 
(mainly permanent stomas vs reconstructive surgery) 
as this may influence the overall decision to undergo 
surgery. We will do this in line with the systematic devel-
opment process specified by IPDAS, ensuring the deci-
sion aid meets minimum standards.24 27
The study objectives are to:
1. Develop a decision aid for use by gastroenterology and 
colorectal surgery teams (consultant surgeons/gas-
troenterologists, stoma/inflammatory bowel disease 
(IBD) nurses) to support adult patients (>18 years of 
age) in their decision about elective surgery, and the 
surgical option they may wish to opt for.
2. Assess the face validity of the decision aid to support 
patients make an informed decision about their pre-
ferred treatment option.
3. Pilot an evaluation study for the acceptability of the 
decision aid in clinical practice. This will use a mixed- 
methods approach to capture the views of:
A. Patients making the treatment decision.
B. Gastroenterology and colorectal surgery health 
professionals supporting the patient through their 
decision.
It is anticipated the evaluation of the PtDA will deter-
mine whether the administration of a PtDA in the 
treatment pathway will better support patients in their 
treatment decisions, as well as providing structure and 
guidance to consultations with patients.
MEthOds And AnAlysIs
The methodology used for this research has been adapted 
from a previously published protocol to develop a PtDA 
for women with cancer to help them make fertility pres-
ervation treatment decisions (Cancer, Fertility and Me), 
led by a member of our research team (GLJ) and funded 
by Yorkshire Cancer Research (S391).25 The protocol 
also follows established guidance from IPDAS and other 
recommended guidance regarding the development of 
PtDA.24 27 The study process is summarised in figure 1.
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Figure 1 Summary of the study stages. PtDA, patient decision aid.
A steering group with relevant expertise to support 
PtDA development is essential.24 Therefore, a steering 
group was created prior to protocol development and 
submission for grant funding to ensure all stakeholders 
were represented. The steering group consists of: 
specialist surgical and gastroenterology clinicians, health 
psychologists with expertise in decision- making, IBD/
stoma nurses, a medical student and patient representa-
tives. All sections of the protocol have been reviewed and 
discussed by the steering group. The PtDA will be devel-
oped across two regional centres (Sheffield Teaching 
Hospitals and Hull and East Yorkshire Hospitals). The 
steering group will hold regular meetings during stage 1 
to decide the content and design of the aid, and will hold 
regular meetings at important stages thereafter. Ethics 
approval was granted on 13 March 2019.
design
Stage 1: development of the PtDA
 Validating patient informational preferences
Our group has already carried out qualitative work 
exploring patient informational preferences when 
considering surgery.26 These results will be validated 
on a national scale by a questionnaire using established 
methodology.15 28 Questionnaire content will include 
demographic data, the control preferences scale29 and 
questions about the preferred content and format of 
preoperative information. This will provide a description 
of whether particular demographic groups of patients are 
amenable to a PtDA, and the preferred content and format 
of such an aid. Questionnaires will be disseminated to a 
number of sites through an established network of IBD 
researchers. Prior to questionnaire development, patients 
will be involved in questionnaire design and refinement 
via a focus group held at Sheffield Teaching Hospitals. 
This will help make the findings generalisable and ensure 
key concepts are included within the questionnaire.
 Synthesising the best available evidence
This will consist of the following stages:
A. Systematic reviews of evidence about the risks and 
benefits of elective surgery and continued medical 
management will be undertaken, as well as a system-
atic review on factors influencing treatment choices. 
A full list of inclusion and exclusion criteria for each 
review is listed in online supplementary appendix ta-
bles S1–S3):
 – A systematic review of outcomes after surgery to in-
form the PtDA using the best available evidence. 
This has been registered on the PROSPERO ( www. 
crd. york. ac. uk/ PROSPERO) database. Methodol-
ogy will include the procedures of subtotal colec-
tomy with permanent end ileostomy, proctocolec-
tomy, ileal- anal pouch anastomosis and ileorectal 
anastomosis. Ileorectal anastomosis will be includ-
ed in the PtDA as our research group notes it is 
a procedure that is offered in some UK centres, 
as well as in centres outside the UK. Its inclusion 
is with the caveat that some centres may not offer 
this operation, and this will be noted in the aid. 
The primary outcome will be quality of life, with 
secondary outcomes covering a wide range of early 
and late complications after surgery.
 – Systematic review of risks and benefits of continued 
medical treatment. This will inform the decision 
aid so that the consequences of continued medical 
treatment—positive and adverse—can be quanti-
fied for patients facing this choice. This has been 
registered on PROSPERO.
 – Systematic review of the factors that may facilitate 
or hinder patients with UC to make medical and 
surgical treatment choices (eg, possible fear of a 
stoma) to ensure these elements are captured and 
addressed in the new resource. This has been regis-
tered on PROSPERO.
B. Focus groups with expert clinicians, nurses and pa-
tients regarding the optimum time to introduce the 
PtDA into the treatment pathway, as well as the opti-
mum content for each group. This will be via a patient 
and public involvement day at Sheffield Teaching Hos-
pitals.
Drafting the PtDA
Once the evidence has been synthesised, the steering 
group will meet to decide the content of the aid. The 
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PtDA will be created using IPDAS guidance,24 27 including 
guidance on balancing options,30 risk presentation,30–33 
eliciting patient values,34 use of patient stories18 and 
enabling readability,35 36 something found to be poor in 
the UC patient literature.23
The content of the aid will be guided by the infor-
mational preference studies and systematic reviews of 
evidence we complete. Significant risks, benefits and 
outcomes and their associated probabilities from our 
systematic reviews will be included. Common topics 
of informational preferences will be discussed by the 
group, and a consensus established on the inclusion. The 
composition of the group, with both expert clinicians and 
patients, will help develop content that meets the require-
ments of both patients and healthcare professionals.
Stage 2: face validity study
The aim of this stage is to assess the PtDA for comprehen-
sion, feasibility and acceptability using key stakeholders—
sometimes referred as learner verification or alpha 
testing.24 37 This will be done with both clinicians and 
patients, using qualitative methodology, and according 
to an established protocol, with which we have extensive 
experience. This will be undertaken across two large sites 
(Sheffield and Hull).
 Sample
A purposive sample of healthcare professionals and 
patients not involved in the steering group will be invited 
to take part in the study. Purposive sampling has been 
chosen to ensure recruitment of a representative sample 
of both healthcare professionals and patients. The Health-
care Professional (HCP) sample will include colorectal 
surgeons, gastroenterologists, IBD nurses and stoma 
nurses. The patient sample will include those who opted 
for surgery, those who considered but declined surgery 
and those currently deliberating treatment options. We 
expect a sample size of 20 participants, with a minimum 
of 10 healthcare professionals and 10 patients, will be 
enough based on previous studies and experience.25 
However, sample size will be guided by data saturation, 
which is in line with good qualitative methods.38–40
 Recruitment
Patients will be identified through the services at the 
two clinical centres by clinicians and nurses. We will also 
advertise stage 2 of the study through the Crohn’s and 
Colitis UK forums. Following this the contact details 
for consenting patients will be passed on to a trained 
researcher and those willing to participate will be sent the 
PtDA for review. Healthcare professionals will be recruited 
from the study sites through purposive sampling. All 
contact details will be stored securely at either Sheffield 
Teaching Hospitals or Leeds Beckett University.
 Data collection
 Qualitative
Consenting clinicians and patients will be posted the PtDA 
and given 1–2 weeks to assess the aid, with a telephone 
interview taking place at the end of the time period. 
Patients and clinicians will provide verbal feedback on 
the aid, focusing on its comprehensibility and ease of use. 
An interview schedule will be created a priori by expert 
members of the steering group. Interviews will be audio 
recorded, digitalised and transcribed for analysis.
 Quantitative
Patients will also be asked to complete a Preparation for 
Decision- Making Questionnaire. The Preparation for 
Decision- Making Questionnaire is a 10- item measure 
which will provide a score on a scale of 0–100.41 The 
higher the score, the higher the perceived levels of prepa-
ration for decision- making—which will provide a vali-
dated quantitative measure of how individuals view the 
usefulness of the PtDA.41
 Data analysis
Interviews will be transcribed and coded using NVivo 
V.11 computer- assisted qualitative data analysis software 
(QSR International, Australia). Analysis will use an induc-
tive thematic approach, outlined by Braun and Clarke 
using a systematic five- step approach: familiarisation, 
generating initial codes, searching for themes, reviewing 
themes and defining and naming themes.40 The themes 
actively generated by the researchers from the data will be 
discussed by the steering group.
The steering group will subsequently refine the aid 
based on the results of this stage. If there are significant 
changes required, a second face validity study will be 
undertaken before progression to stage 3.
Stage 3: evaluation study
The aim of this pilot is to field test the PtDA in clin-
ical practice, as there may be clinical contextual factors 
impacting the PtDA. This is typically referred to as beta 
testing.24 This will follow a mixed- methods approach 
across the same two sites as in stage 2. We aim to recruit 
15 patients at each site for a minimum sample size of 30—
comparable with other PtDA pilots in the literature.42 A 
summary of stage 3 is provided in figure 2.
 Quantitative
Sample and recruitment
All patients over the age of 18 who receive consultation 
about the possibility of undergoing elective surgery will 
be included. This includes consultations with clinicians 
and specialist nurses. We will use the referral model 
for implementing PtDA—a process where the clinician 
mentions the PtDA to eligible patients during consulta-
tion about treatment options, and indicates the clinical 
researchers will discuss the study following the consul-
tation should the patient consent to involvement.43 
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Figure 2 Summary of stage 3—evaluation study. PtDA, patient decision aid; STAI-6, Spielberger State- Trait Anxiety 
Inventory-6.
Eligible patients identified by the clinical team will be 
invited to participate by the researcher(s) with the clin-
ical team immediately following the consultation if they 
are present, or within a week if the patient consents to 
contact outside the clinical setting by a member of the 
research team.
Data measures and collection
Patients will be asked to complete a series of question-
naires at baseline (first clinic appointment) before 
administration of the PtDA. Patients will be instructed 
not to open or view the PtDA before completion of the 
questionnaires at baseline. Patients will then complete 
the same questionnaires at timepoint 1 (immediately 
before the second clinic appointment). Questionnaires 
will include a measure of anxiety (Spielberger State- Trait 
Anxiety Inventory-6),44 Stage of Decision- Making45 and 
Decisional Conflict Scale46 as recommended by IPDAS.24 
All questionnaires will provide a quantitative measure to 
allow comparison before and after use of the PtDA.
Analysis
Summary statistics will be reported for demographics 
and other relevant indicators. For decisional outcome 
measures we will use paired sample t- tests to calculate 
mean changes from baseline to timepoint 1. CIs will be 
set at 95% a priori, meaning values will be significant if 
p≤0.05.
 Qualitative
Sample and recruitment
Healthcare professionals and patients will be asked to 
take part in semistructured interviews. We will under-
take 10 interviews with patients and 10 with healthcare 
professionals (IBD/stoma nurses, gastroenterology and 
surgical clinicians), although this will be guided by data 
saturation, in line with established protocols in qualitative 
research.38 40 The interviews will give a deeper insight into 
the experience of using the aid from a patient and clini-
cian perspective in clinical practice. Clinician interviews 
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will also explore views regarding the timing of the aid in 
the treatment pathway, establishing if the time previously 
eliciting in stage 1 is also the optimum time for additional 
sites. Patients will be recruited using purposive sampling 
from the sample of 30 that have taken part in the quan-
titative analysis of stage 3. Prior to interview, patients will 
receive an information sheet, and on the day of interview 
the patient will be issued a consent form which will be 
cosigned with the interviewer.
Data collection
An interview transcript will be created by expert members 
of the steering group a priori. Questions will be adapted 
from the transcript used in stage 2, with additional ques-
tions to add depth and clarity into the interpretation of 
the quantitative results. Questions will also focus on the 
PtDA usefulness in helping the patient decide between 
treatment options.
Analysis
All interviews will be transcribed and coded as per the 
same methods in stage 2. Framework analysis, an anal-
ysis designed specifically for applied health and policy 
research,47 will be used to identify recurrent themes. 
Recurrent themes will be discussed with the steering 
group and subsequent refinement of the PtDA will take 
place.
Patient and public involvement
A patient representative who had prior experience of 
the decision at question in our PtDA was recruited to the 
steering committee prior to protocol development. Our 
representative contributed to overall protocol develop-
ment, particularly the feasibility of stage 3 to the public. 
It was anticipated our patient representative would 
contribute heavily to the design and format of the PtDA, 
commenting on readability, layout and presentation of 
information. Patient representative did not contribute to 
study recruitment. Patients will also be involved in ques-
tionnaire development (stage 1) and design via a focus 
group.
EthICs And dIssEMInAtIOn
Ethical considerations
Research ethics approval from North East–Tyne & Wear 
South Research Ethics Committee (Ref: 19/NE/0073) 
and Health Research Authority approval (Ref: 257044) 
have been granted. Written, signed consent will be 
obtained from all participants at stages where it is 
necessary. Participants will have the right to withdraw 
from the research process at any time throughout the 
study. All interviews will be kept strictly confidential 
and patients and healthcare professionals will be given 
a study ID number to maintain this confidentiality. 
Participation in this study will not interfere with usual 
patient care.
dissemination
This is a multidisciplinary, collaborative project with 
clinicians and patients. This will allow us to disseminate 
the research and its milestones into both the National 
Health Service (NHS) and the wider healthcare commu-
nity through a variety of local, national and international 
forums such as charities and international meetings. We 
will also seek to index an online version of the PtDA in the 
Decision Aid Library Inventory once we have completed 
and analysed the paper version. We will also seek to index 
the NHS library of decision aids. A web- based version 
of the PtDA will also allow dissemination through the 
internet which is widely accessible to patients worldwide. 
Social media such as Twitter and blogs can also be used 
to signpost the availability of the instrument to both clini-
cians and patients.
We plan to impact the academic and clinical commu-
nity more widely through a combination of conference 
presentations and peer- reviewed publications.
The primary output of this study is the PtDA, available 
in print. This will then be evaluated for effectiveness in a 
larger study, outside the costings of this grant application. 
Once fully evaluated it will be promoted more widely 
through social media, charity websites, professional 
organisations and academic sources.
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